PE20040042A1 - Composicion farmaceutica que comprende esteres de etonogestrel - Google Patents

Composicion farmaceutica que comprende esteres de etonogestrel

Info

Publication number
PE20040042A1
PE20040042A1 PE2003000508A PE2003000508A PE20040042A1 PE 20040042 A1 PE20040042 A1 PE 20040042A1 PE 2003000508 A PE2003000508 A PE 2003000508A PE 2003000508 A PE2003000508 A PE 2003000508A PE 20040042 A1 PE20040042 A1 PE 20040042A1
Authority
PE
Peru
Prior art keywords
ester
etonogestrel
contraceptive
pharmaceutical composition
composition including
Prior art date
Application number
PE2003000508A
Other languages
English (en)
Inventor
Dirk Leysen
Der Louw Jaap Van
Nijs Henrik De
Arij Jan Grootenhuis
Der Voort Hendrikus Adrianus Antonius Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20040042A1 publication Critical patent/PE20040042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UN ANTICONCEPTIVO Y/O KIT DE HRT, QUE COMPRENDE: A)UNA CANTIDAD ANTICONCEPTIVA DE 25 mg A 200 mg DE UN ESTER DE ETONOGESTREL DE LARGA ACCION CON UNA LONGITUD DE CADENA GRASA DE C7-C15, SIENDO DICHO ESTER UNDECANOATO DE ETONOGESTREL Y/O DECANOATO DE ETONOGESTREL Y/O DODECANOATO DE ETONOGESTREL; Y, B)50 mg A 400 mg DE UN ESTER ANDROGENO QUE ES UNDECANOATO DE MENT. LA COMPOSICION TIENE APLICACION COMO UN ANTICONCEPTIVO FEMENINO Y MASCULINO QUE A SU VEZ PUEDE USARSE EN EL TRATAMIENTO Y PREVENCION DE LOS DESORDENES GINECOLOGICOS FEMENINOS, COMO LA ENDOMETRIOSIS, MENORRAGIA, SINDROME PREMENSTRUAL Y DISMENORREA
PE2003000508A 2002-05-30 2003-05-26 Composicion farmaceutica que comprende esteres de etonogestrel PE20040042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30

Publications (1)

Publication Number Publication Date
PE20040042A1 true PE20040042A1 (es) 2004-01-31

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000508A PE20040042A1 (es) 2002-05-30 2003-05-26 Composicion farmaceutica que comprende esteres de etonogestrel

Country Status (27)

Country Link
US (1) US20050222114A1 (es)
EP (1) EP1513588B1 (es)
JP (1) JP2005532336A (es)
KR (1) KR20050005507A (es)
CN (1) CN1655848A (es)
AR (1) AR040129A1 (es)
AT (1) ATE394140T1 (es)
AU (1) AU2003246740B2 (es)
BR (1) BR0311248A (es)
CA (1) CA2487293A1 (es)
DE (1) DE60320786D1 (es)
ES (1) ES2305498T3 (es)
HK (1) HK1072568A1 (es)
HR (1) HRP20041127A2 (es)
IL (1) IL165125A0 (es)
IS (1) IS7537A (es)
MX (1) MXPA04011798A (es)
NO (1) NO20044903L (es)
NZ (1) NZ536618A (es)
PE (1) PE20040042A1 (es)
PL (1) PL373295A1 (es)
RS (1) RS101004A (es)
RU (1) RU2322986C2 (es)
TW (1) TW200400041A (es)
UA (1) UA80703C2 (es)
WO (1) WO2003101374A2 (es)
ZA (1) ZA200409498B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
PE20210155A1 (es) * 2017-10-19 2021-01-26 Evestra Inc Anticonceptivos de profarmacos de progestina de accion mas prolongada
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
US20230227492A1 (en) * 2020-06-11 2023-07-20 The Usa As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
WO1995017896A1 (fr) * 1993-12-27 1995-07-06 Akzo Nobel N.V. Preparation pour absorption par voie percutanee
JPH11509222A (ja) * 1995-07-17 1999-08-17 シェリング アクチェンゲゼルシャフト １３−エチル−１７β−ヒドロキシ−１１−メチレン−１８，１９−ジノル−１７α−プレグン−４−エン−２０−イン−３−オンのエステルを含む経皮投与のための剤
WO1999067270A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
CA2333985C (en) * 1998-06-19 2007-04-10 Dirk Leysen Testosterone derivative
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Also Published As

Publication number Publication date
ATE394140T1 (de) 2008-05-15
KR20050005507A (ko) 2005-01-13
BR0311248A (pt) 2005-03-15
AU2003246740B2 (en) 2009-01-08
JP2005532336A (ja) 2005-10-27
CA2487293A1 (en) 2003-12-11
EP1513588B1 (en) 2008-05-07
HK1072568A1 (en) 2005-09-02
AR040129A1 (es) 2005-03-16
CN1655848A (zh) 2005-08-17
UA80703C2 (en) 2007-10-25
WO2003101374A2 (en) 2003-12-11
US20050222114A1 (en) 2005-10-06
MXPA04011798A (es) 2005-03-31
IL165125A0 (en) 2005-12-18
RS101004A (en) 2006-10-27
ES2305498T3 (es) 2008-11-01
NZ536618A (en) 2007-06-29
HRP20041127A2 (en) 2005-02-28
RU2004138809A (ru) 2005-06-10
DE60320786D1 (de) 2008-06-19
WO2003101374A3 (en) 2004-02-26
RU2322986C2 (ru) 2008-04-27
EP1513588A2 (en) 2005-03-16
IS7537A (is) 2004-11-18
PL373295A1 (en) 2005-08-22
ZA200409498B (en) 2006-05-31
AU2003246740A1 (en) 2003-12-19
TW200400041A (en) 2004-01-01
NO20044903L (no) 2005-02-25

Similar Documents

Publication Publication Date Title
CY1106064T1 (el) Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
ATE478129T1 (de) Kerzenwachs auf triacylglycerin-basis
ECSP066670A (es) Prodroga florfenicol con mejor solubilidad en agua
GB0314624D0 (en) Inflammatory disease treatment
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
AR029687A1 (es) Composiciones y metodos para el manejo del peso corporal
UA102478C2 (en) Capsule composition
RU2012125827A (ru) Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
AR054123A1 (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
EA200801602A1 (ru) Эмульсия
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
ECSP088571A (es) Control de la estabilidad de la forma de dosificacion de cci-779 a traves del control de impurezas de sustancias de farmaco
AR085090A1 (es) Formulacion transdermica de testosterona, metodo de tratamiento
CL2012002705A1 (es) Composicion farmaceutica que comprende: a) 0,1-20% de ropivacaina,bupivacaina o levobupivacaina, b) 15 a 70% en peso de un monoglicerido de acido graso de cadena larga o sus mezclas, c) 5 a 60% de un acido graso libre saturado o instaurado de cadena larga y d)menos de 30% de agua; uso para reducir el dolor.
PE20040992A1 (es) Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev
PE20040042A1 (es) Composicion farmaceutica que comprende esteres de etonogestrel
BRPI0511079A (pt) usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
CL2020000695A1 (es) Composición que comprende aceite vegetal y vinagre de sidra de manzana.
DE60135980D1 (de) Vergiessbare backfettzusammensetzung
CO5160323A1 (es) Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih
BR112016025126A8 (pt) Formulação líquida compreendendo composto neutralizante de gm-csf
WO2007027476A3 (en) Treating premature ejaculation using gabapentin and pregabalin prodrugs
CO2023013397A2 (es) Compuestos de tienopirrol

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FC Refusal